Browse
Submit Data
Databases
API
Help

Metabolomics,Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

13 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Lack of associations of microRNAs with severe NAFLD in people living with HIV: Discovery case-control study

ABSTRACT: The aim of this discovery case-control study was to identify patterns of differential expression of microRNAs in people living with HIV (PLWH) and assess their diagnostic value for non-alcoholic fatty liver disease (NALFD). Cases were defined as patients with severe NAFLD and controls as patients without NAFLD, characterized using the controlled attenuation parameter (CAP). Cases and controls were matched 1:1 for age, sex, body mass index, CD4+ lymphocyte count, active HCV infection, and ART regimen. Serum 2,083 simultaneous microRNA transcripts were analyzed using HTG technology and compared between cases and controls. Forty-five patients, 23 cases, and 22 controls were included in the study. In the analysis of the expression pattern of the 2,083 microRNAs, no differential expression patterns were found between both groups of patients included in the study. Analysis of the microRNA transcriptome profile of nonobese PLWH with severe NAFLD did not appear to differ from that of patients without NAFLD. Thus, microRNA might not serve as a proper biomarker for predicting severe NALFD in this population.

INSTRUMENT(S): HTG EdgeSeq Processor; Applied Biosystems 7500 fast Real-time PCR Instrument, NextSeq 550

ORGANISM(S): Homo sapiens

SUBMITTER: Mario Frias

PROVIDER: E-MTAB-12974 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Json Xml

Similar Datasets

RNA-seq of human with nonalcoholic fatty liver disease against untreated controls

Project description:We analyzed the transcriptome for drug metabolism genes of 35 human (17 healthy control (HC), and 18 nonalcoholic fatty liver disease (NAFLD)) liver tissues, obtained during laparoscopic cholecystectomy. The aim of our study is to identify the drug metabolism genes significantly regulated by NAFLD at the transcriptome level.

2022-12-19 | E-MTAB-12445 | biostudies-arrayexpress

Liver transcriptome of biopsy-proven NAFLD patients at different stages of the disease

Project description:We investigated the hepatic transcriptome of 58 biopsy-proven NAFLD patients at multiple stages of the disease (NAFL, NASH with mild fibrosis, NASH with advanced fibrosis) with the aim of describing the pathophysiological events driving the development and progression of NASH.

2021-04-14 | E-MTAB-9815 | biostudies-arrayexpress

RNA-Seq CAGE (Cap Analysis of Gene Expression) analysis of mice cells in RIKEN FANTOM5 project

Project description:This experiment captures the expression data reported by the RIKEN FANTOM5 project ( http://fantom.gsc.riken.jp/5/ ), focusing on mice cell data which was deposited in the seqence read archive (SRA) under study accession DRP001032 (https://www.ebi.ac.uk/ena/data/view/DRP001031 ) . The samples in this experiment can also be found on a dedicated page of the FANTOM website: http://fantom.gsc.riken.jp/5/sstar/Browse_samples. Since this is CAGE analsyis, gene expression data is reported by FANTOM5 in TPMs (tags per milliion) for gene promoters. This is in conjunction with E-MTAB-3577 (http://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-3577/)

2015-05-14 | E-MTAB-3578 | biostudies-arrayexpress

RNA-Seq CAGE (Cap Analysis of Gene Expression) analysis of mice tissue in RIKEN FANTOM5 project

Project description:This experiment captures the expression data reported by the RIKEN FANTOM5 project ( http://fantom.gsc.riken.jp/5/ ), focusing on mice tissue data which was deposited in the sequence read archive (SRA) under study accession DRP001032 (https://www.ebi.ac.uk/ena/data/view/DRP001031 ) . The samples in this experiment can also be found on a dedicated page of the FANTOM website: http://fantom.gsc.riken.jp/5/sstar/Browse_samples. Since this is CAGE analysis, gene expression data is reported by FANTOM5 in TPMs (tags per milliion) for gene promoters. This is in conjunction with E-MTAB-3578 (http://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-3578/)

2015-05-14 | E-MTAB-3579 | biostudies-arrayexpress

RNA-Seq CAGE (Cap Analysis of Gene Expression) analysis of human tissues in RIKEN FANTOM5 project

Project description:This experiment captures the expression data reported by the RIKEN FANTOM5 project ( http://fantom.gsc.riken.jp/5/ ), focusing on tissue/organism part data which was deposited in the seqence read archive (SRA) under study accssion DRP001031 ( https://www.ebi.ac.uk/ena/data/view/DRP001031 ) . The samples in this experiment can also be found on a dedicated page of the FANTOM website: http://fantom.gsc.riken.jp/5/sstar/Browse_samples . Since this is CAGE analsyis, gene expression data is reported by FANTOM5 in TPMs (tags per milliion) for gene promoters.

2015-02-28 | E-MTAB-3358 | biostudies-arrayexpress

Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: diagnostic and mechanistic relevance

Project description:Background & Aims: Serum microRNAs (miRNAs) levels are known to change in non-alcoholic fatty liver disease (NAFLD) and may serve as useful biomarkers. This study aimed to profile miRNAs comprehensively at all NAFLD stages. Methods:We profiled 2,083 serum miRNAs in a discovery cohort (183 NAFLD cases representing the complete NAFLD spectrum and 10 population controls). MiRNA libraries generated by HTG EdgeSeq were sequenced by Illumina NextSeq. Selected serum miRNAs were profiled in 372 additional NAFLD cases and 15 population controls by quantitative reverse transcriptase-polymerase chain reaction. Results: Levels of 275 miRNAs differed between cases and population controls. Fewer differences were seen within individual NAFLD stages but miR-193a-5p consistently the showed increased levels in all comparisons. Relative to NAFL/NASH with mild fibrosis (stage 0/1), three miRNAs (miR-193a-5p, miR-378d and miR378d) were increased in cases with NASH and clinically significant fibrosis (stage 2-4), seven (miR193a-5p, miR-378d, miR-378e, miR-320b, c, d & e) increased in cases with NAFLD Activity Score (NAS) 5-8 compared with lower NAS, and three (miR-193a-5p, miR-378d, miR-378e) increased but one (miR-19b-3p) decreased in steatosis, activity, and fibrosis "activity" (SAF-A) score 2-4 compared with lower SAF-A. The significant findings for miR-193a-5p were replicated in the additional NAFLD cohort. Studies in Hep G2 cells showed that following palmitic acid treatment, miR-193a-5p expression decreased significantly. Gene targets for miR-193a-5p were investigated in liver RNAseq data for a case subgroup (n=80); liver GPX8 levels correlated positively with serum miR-193a-5p. Conclusions: Serum miR-193a-5p levels correlate strongly with NAFLD activity grade and fibrosis stage. MiR-193a-5p may have a role in the hepatic response to oxidative stress and is a potential clinically tractable circulating biomarker for progressive NAFLD.

2022-01-31 | GSE185062 | GEO

Dyslipidemia Alters HDL Metabolism and Function in NAFLD

Project description:Dyslipidemia and inflammation play key roles in the pathogenesis of both nonalcoholic fatty liver disease (NAFLD) and atherosclerosis. NAFLD, particularly its severe form nonalcoholic steatohepatitis (NASH) is associated with increased cardiovascular disease (CVD) risk. HDL (high density lipoprotein- also a CVD risk) are decreased in NAFLD but whether HDL function is abnormal in NAFLD is unknown. Furthermore, it is unknown whether dyslipidemia contributes to reduced HDL function in NAFLD and whether hepatic inflammation further impairs HDL function in patients with NASH. Therefore, the aim of this study was to investigate HDL function and to examine the effect of dyslipidemia and inflammation on HDL metabolism in patients with biopsy-proven simple steatosis (SS) and NASH. RESULTS: Compared to controls, SS and NASH subjects had significantly higher levels of plasma triglyceride, insulin, and were more insulin resistant (HOMA, P<0.05) with no differences in total cholesterol, HDL cholesterol, ApoB100 and ApoAI levels. NAFLD patients had increased production and degradation rates of both HDLc and ApoAI that resulted in their levels remaining stable. The degradation rates also were increased of other HDL proteins, including ApoAII, ApoAIV, vitamin D-binding protein, and complement 3 (all P<0.05). NAFLD patients had increased activities of LCAT and CETP, indicating altered HDL lipidation. NAFLD induced alterations in HDL metabolism were associated with reduced anti-oxidant but increased pro-inflammatory activity of HDL. However, no differences were observed in either HDL function or the kinetics of HDLc and HDL proteins between SS and NASH subjects.

2019-08-12 | PXD010199 | Pride

Transcriptomic analysis of induced pluripotent stem cells (iPSC) and differentiated hepatocytes (iPSC-Heps) from a cohort of healthy subjects and patients with nonalcoholic fatty liver disease (NAFLD)

Project description:We report that the transcriptomic profiles of iPSC-Heps from NAFLD patients are distinct from those of healthy controls. This is in contrast to the transcriptomic profiles of the parent iPSC, which are similar between NAFLD patients and healthy controls.

2021-06-30 | GSE138312 | GEO

RNA-seq of human liver biopsies from patients with NAFLD, patient with cirrhosis, and healthy controls under both fasting and postprandial conditions.

Project description:The data provides a unique opportunity for investigating the differences in the hepatic transcriptome in health and liver disease through studying gene expression in a cohort of patients with NAFLD, cirrhosis, and healthy controls. The randomization of patients and healthy controls between the fasting and fed state further enables exploration of differences in the liver transcriptome.

2023-08-27 | E-MTAB-12807 | biostudies-arrayexpress

COVID-19 Suceptibility Florida

Project description:To reveal genetic determinants of susceptibility to COVID-19 severity in the population and further explore potential immune-related factors, we performed a genome-wide association study on 284 confirmed COVID-19 patients (cases) and 95 healthy individuals (controls). We compared cases and controls of European (EUR) ancestry and African American (AFR) ancestry separately. To further exploring the linkage between HLA and COVID-19 severity, we applied fine-mapping analysis to dissect the HLA association with mild and severe cases.

2023-01-17 | GSE211972 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data